Browsing Tag
Acute myeloid leukemia
38 posts
How Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia patients
Find out how Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia, transforming treatment and investor sentiment alike.
CERo Therapeutics moves forward in Phase 1 AML study as CER-1236 passes first-dose safety review
CERo Therapeutics completes first cohort of its Phase 1 AML trial with no dose-limiting toxicities—discover how CER-1236 could reshape immunotherapy.
Hemogenyx Pharmaceuticals stock jumps after third patient in CAR-T AML trial shows safety and early efficacy
Hemogenyx Pharmaceuticals (LSE: HEMO) stock jumps 24% after third patient treated in CAR-T AML trial shows safety and early efficacy.
Moleculin Biotech (NASDAQ: MBRX) launches stock offering to support pivotal cancer drug trial and IND filings
Moleculin Biotech to raise $5.9M to fund its Phase 3 trial for Annamycin and expand oncology pipeline. Explore what this means for AML treatment and investors.
Senti Biosciences gets FDA orphan drug status for SENTI-202 in relapsed AML treatment
Senti Biosciences earns FDA orphan drug designation for SENTI-202 in AML. Find out how this logic-gated CAR-NK therapy could reshape leukemia treatment.
CERo Therapeutics gets FDA boost for CER-1236, eyes breakthrough in AML cell therapy
CERo Therapeutics secures FDA orphan drug status for CER-1236 in AML, advancing its novel CER-T immunotherapy platform. Read what this means for investors.
Moleculin Biotech moves forward with pivotal Annamycin trial in AML after FDA backing
Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing innovative treatments for acute myeloid leukemia,…
Hemogenyx Pharmaceuticals launches Phase I AML trial for HG-CT-1 CAR-T therapy
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a leading biopharmaceutical company, has taken a significant step forward in the fight…
Aptevo Therapeutics achieves major breakthrough with mipletamig in acute myeloid leukemia
Aptevo Therapeutics has unveiled remarkable findings from Cohort 1 of its RAINIER clinical trial for mipletamig, a bispecific…
OncoVerity accelerates AML treatment with Series A extension
OncoVerity, a leader in integrating bioinformatics with oncology drug development, has closed a Series A extension financing round,…